Mission Statement


BiOrigin aims to support the establishment and management of early-stage life science companies, primarily within the Novo Seeds portfolio.

Strategic and Operational Support

BiOrigin provides different types of strategic and operational support to companies and projects in order to help them steer through the critical start-up and subsequent growth phase.


BiOrigin is the “Entrepreneur-in-Residence” team for Novo Seeds

What we do


We help clients advance new therapies by designing R&D plans and providing management services to support projects across the spectrum of development


We support the fund-raising process by devising strategies to access a broad network of private and venture capital, as well as supporting efforts for soft sources of funding. Once financed, we also offer financial management services from accounting, budgeting, cost controlling and reporting.


We help clients develop their partnering strategies and navigate the entire business development process, providing an end-to-end service that includes generating partnering leads, intelligence gathering, deal structuring, negotiations, and alliance management


We provide the full range of corporate development services from strategizing and contracting to human resourcing and operations

The Team

Casper Tind Hansen
Casper has 15 years of expertise in pharma, biotech, and venture capital. He has taken on various roles in Marketing and Business Development at Lundbeck and Nycomed, he was part of the investment team at Novo Ventures, and has been CEO of Pcovery, a Danish Discovery stage biotech company. Casper is the co-founder of Orphazyme and Embark Biotech. He holds a M.Sc in Human Biology from the University of Copenhagen.

Ian Laquian
Ian has over 15 years of experience in building companies, franchises, portfolios and products. He has had senior roles with increasing responsibility within R&D, Business Development, and Marketing at Nycomed and Takeda; overseeing development of key assets in Alzheimer’s Disease, Schizophrenia and Depression. Ian holds a B.Sc. in Biochemistry from the University of Waterloo, and a M.Sc. in Biochemistry and MBA from the University of Ottawa.

Jakob Dynnes Hansen
More than 25 years of experience from biotech and financing. Previously, CFO of Evolva, a Swiss public biotech company, Nuevolution and Zealand Pharma, Senior member of Corporate Finance Team at Unibank (now Nordea), Head of Market Research at Novo Nordisk. MSc (Econ.,University of Copenhagen), MBA (INSEAD)

Advisory Board

Hans Schambye
CEO, Galecto

Jürgen Heitmann
Previously Novartis

Kristine Peterson
Director at Dermtreat